BackCaliPharms Overview

CaliPharms Receivables

Track CaliPharms's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

CaliPharms Receivables History

Loading

CaliPharms vs. peers: Receivables Comparison

Loading

CaliPharms Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

CaliPharms (KGET) FAQ

As of the most recent data (September 2014), KGET shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KGET's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether CaliPharms is outperforming or lagging.

Tracking KGET's receivables over time shows whether CaliPharms is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has CaliPharms's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

CaliPharms's receivables is $0; compare it with other Industrials names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.